How
will the technology impact the overall probability of success
in preclinical drug development?
SPECT
directly affect the probability for success in preclinical
drug development, and will likely shorten the process thereby
saving money.

Table
comparing the functional imaging technologies...fMRI, PET,
CT, SPECT ...etc.
SPECT is an acronym for Single Photon Emission Computed
Tomography and is used in nuclear medicine procedures to
image the function of body organs. Gamma camera SPECT
has insufficient resolution for diagnostic brain
imaging. The chart at right illustrates the "utility"
for brain function imaging versus cost. MRI (magnetic
resonance imaging) and CT (x-ray computed tomography) are
used for brain anatomy rather than function.
"Functional" MRI (fMRI) is expensive and limited in the
variety of procedures that it is capable of performing.
PET (positron emission tomography) has considerable
versatility for functional brain imaging but is very
expensive, becoming more so with increasing versatility and
resolution. The MollyQ SFP system provides the best
combination of high resolution and sensitivity for functional
brain scans at the lowest cost.
How
does the technology work?
Functional
imaging in nuclear medicine SPECT begins by "tagging" a
biologically active molecule with a radioactive atom.
This is called a "radiopharmaceutical" or "biomarker."
A simple example of this process is to use molecules tagged
with radioactive technetium atoms that very rapidly pass from
brain capillaries into the surrounding brain tissue where
they "stick". When injected into the
bloodstream, these tagged molecules are taken up in brain
tissue where the blood flow is greatest. This occurs in
the small areas where the neurons are momentarily most active
(i.e., thinking). The additional neuronal metabolic
activity demands more oxygen and glucose to which the brain's
circulation quickly responds by locally increasing blood
flow. The distribution of the resulting technetium
concentration can then be detected externally and a map of
brain activity (function) "reconstructed."
The distribution of radiopharmaceuticals can be mapped by
gamma cameras or the NeuroPhysics "MollyQ™"
scanner. The latter has major advantages in both
resolution and sensitivity.
The operation of the MollyQ™ scanner is the same as the
scanning optical microscopes used to obtain high-resolution,
three-dimensional images of biological tissue. A highly
focused point of light is mechanically moved about in three
dimensions in such a way as to uniformly sample the volume
under observation. Because the energetic gamma rays
emitted by the single-photon biomarkers cannot be focused by
conventional optics, the MollyQ™ camera uses
proprietary gamma lenses™ for this purpose. This
is called scanning focal-point technology (SFP) and is unique
to the MollyQ™. Other SPECT devices use "gamma
cameras" that work well with other body organs but do not
have the resolution for imaging the functioning of the
incredibly complex human brain.
The MollyQ™ is available in three models. The
standard model has an aperture of 175 mm and is designed for
high resolution imaging of the primate brain. Because
of its high resolution, it has been extensively used for
primates and event tested on rats. Please see
abstract
from SNM Convention. Two new versions just for small animals
including mice are readying for production. The MollyQ™
50 is available now and the MollyQ™ 30 will be ready
first Q' 2007. The SPF technology described above is
"scalable" so that the new, half-size version will have a
factor of two, improvement in resolution.
What
will be the impact of the technology of drug
discovery
and drug development?
While
we at NeuroPhysics do not have the expertise to fully answer
this question, we believe the major impact will be to
substantially shorten drug discovery and development
times. Less animal testing will be needed and the same
animal can often be used in repeated or serial studies.
A wealth of information is available from the AMI
[1]
Dr. John Seibyl has used the standard MollyQ™ for
Parkinson's research using a primate
model.[2]
What
is the applicability of the technology to animals? to
humans?
As
has been discussed above, the standard MollyQ™ has been
extensively used for human and primate brain research.
Over 100 research papers have been published. Any
animal that can fit into the 175 mm aperture may be
scanned. The small animal versions are ideal for mice
and rats. All versions of the SFP technology have equal
or better resolution than PET scanners with the same
apertures.
What
disease areas can the technology be used for (CNS,
respiratory, immunology - US; cardio, bone density - Europe)
and very importantly -toxicology and
pathology?
Although
the standard MollyQ™ has been used for CNS studies,
there is no reason to believe that it and the small animal
MollyQ™ cannot be applied to all of the above within
the
aperture limits of either scanner.
What
resources are needed to implement the technology in-house,
especially compared to PET ... cyclotron, radiopharm lab,
FTEs, etc?
SPECT
technology using available radiopharmaceuticals requires
little more additional facilities than the scanner and a
place for it. If you want to label experimental
molecules, chemistry facilities are required with the
additional capability for handling low-level
radioisotopes.
What
types of animals can be imaged?
Any
animal that can pass through the 175 mm aperture of the
standard scanner or the 50 mm and 30 mm apertures of the
small animal versions of the
MollyQ™.
What
type of resolution (3-D) can be expected?
Imager
performance is a compromise between resolution and field of
view. The more restricted the FOV, the sharper can be the
focus and the better the resolution. But, for any FOV, thanks
to its Photon Lens concept, MollyQ™ offers the best
combination of resolution, sensitivity, and uniformity that
can be had with present technology. In any event, the
ultimate resolution will be determined by the number of
photons detected and the object contrast. This is true
of PET as well.

[1]
Academy of Molecular Imaging (www.ami-imaging.org).
[2]
John Seibyl, MD, PhD (jseibyl@indd.org).